^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Adenocarcinoma

    Related cancers:
    1d
    SWAT-BE: Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance (clinicaltrials.gov)
    P=N/A, N=2298, Recruiting, University of Colorado, Denver | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    2d
    Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer (clinicaltrials.gov)
    P1/2, N=186, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • HER-2 expression
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    2d
    CH CARE: Clonal Hematopoiesis Chemotherapy and Radiation Effects Study (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Dana-Farber Cancer Institute
    New trial
    3d
    Prevalence of heterozygous and homozygous 9p21 deletions in human cancer: a tissue microarray study on 4,999 tumors from 125 different tumor types. (PubMed, Mol Med)
    These data provide a comprehensive overview on the prevalence on homozygous and heterozygous 9p21 deletions in cancer and demonstrate that different cancer types markedly differ in their ratio of homozygous/heterozygous 9p21 deletions. The strong concordance between homozygous 9p21 deletions and absent MTAP immunostaining highlights the effectiveness of immunohistochemistry in detecting MTAP deficiency.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
    8d
    Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO (2025-524048-36-00)
    P2/3, N=212, Not yet recruiting, Gruppo Oncologico Del Nord Ovest
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium
    8d
    Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial (clinicaltrials.gov)
    P=N/A, N=1010, Not yet recruiting, Mayo Clinic | Initiation date: Jun 2026 --> Dec 2026
    Trial initiation date
    9d
    Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice (clinicaltrials.gov)
    P=N/A, N=726, Active, not recruiting, Bristol-Myers Squibb
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab)
    9d
    NCI-2019-07966: Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma (clinicaltrials.gov)
    P2, N=52, Recruiting, University of Wisconsin, Madison | Trial completion date: Dec 2027 --> May 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • Onivyde (nanoliposomal irinotecan)
    10d
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Recruiting, Yale University | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date • Circulating tumor DNA
    10d
    CIT-SEQ: Determining Minimal Residual Disease Using ctDNA Deep Sequencing (clinicaltrials.gov)
    P=N/A, N=34, Recruiting, Masaryk Memorial Cancer Institute
    New trial • Minimal residual disease • Circulating tumor DNA
    10d
    Spatial SRY-Box Transcription Factor 2 Expression and Stemness-Associated Markers Refine Risk Stratification in Barrett's Esophagus: A Digital Pathology Study of 217 Patients. (PubMed, J Clin Med Res)
    Spatial remodeling of SOX2 expression is strongly associated with dysplasia grade and neoplastic progression in BE. Integration of SOX2 spatial metrics with established biomarkers may improve risk stratification beyond conventional histopathologic assessment.
    Clinical • Journal
    |
    CDH1 (Cadherin 1) • SOX2 • CDX2 (Caudal Type Homeobox 2) • YBX1 (Y-Box Binding Protein 1)
    11d
    Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO (2025-524048-36-00)
    P2/3, N=172, Not yet recruiting, Gruppo Oncologico Del Nord Ovest
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium